Eisai to Transfer Royalty Rights for Tazemetostat to Royalty Pharma Outside Japan

 Eisai to Transfer Royalty Rights for Tazemetostat to Royalty Pharma Outside Japan

Eisai Reports Results of Fycompa (perampanel) in P-III FREEDOM Study for Patients with Newly Diagnosed or Untreated Partial Onset Seizures

Shots:

  • Eisai to receive $110M upfront and $220M on marketing approval for tazemetostat in the US for certain indications and Royalty Pharma to get rights to receive royalties from Epizyme on sales outside of Japan
  • In 2015, Epizyme and Eisai made amendment in their agreement for Tazemetostat candidate where Eisai will develop and commercialize in Japan paying royalties to Epizyme for sales in Japan and Epizyme will develop and commercialize outside Japan paying development and regulatory milestones plus royalties on net sales of tazemetostat in all regions outside of Japan
  • Tazemetostat is an inhibitor of epigenetic enzyme EZH2 and Eisai is evaluating it in P-II for B-cell non-Hodgkin’s lymphoma in Japan

Click here to­ read full press release/ article | Ref: Eisai | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post